Clinical qualification of plasma androgen receptor (pAR) status and outcome on abiraterone acetate (AA) plus prednisone or dexamethasone ( plus P/D) in a phase II multi-institutional study in metastatic castration resistant prostate cancer (mCRPC).

被引：0
|
作者：
Jayaram, Anuradha
Wingate, Anna
Sharabiani, Mansour Taghavi Azar
Wetterskog, Daniel
Calabro, Fabio
Barwell, Lorraine
Arlt, Weibke
Merseburger, Axel Stuart
Feyerabend, Susan
Berruti, Alfredo
Lefresne, Florence
Shen, Dong
Gormley, Michael
Kapoor, Gurpreet
Li, Weimin
Jones, Robert J.
Sternberg, Cora N.
Tombal, Bertrand F.
Attard, Gerhardt
机构：
[1] Inst Canc Res, Sutton, Surrey, England
[2] Royal Marsden NHS Trust Fdn, Sutton, Surrey, England
[3] Inst Canc Res, London, England
[4] Royal Marsden NHS Fdn Trust, London, England
[5] San Camillo Forlanini Hosp, Rome, Italy
[6] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[7] Univ Birmingham, Birmingham, W Midlands, England
[8] Univ Hosp Schleswig Holstein Campus Luebeck, Dept Urol, Lubeck, Germany
[9] Studienpraxis Urol, Nurtingen, Germany
[10] Univ Brescia, Spedali Civili Hosp, Med Oncol, Brescia, Italy
[11] Janssen Cilag, Paris, France
[12] Janssen Res & Dev LLC, Spring House, PA USA
[13] LabConnect LLC, Sci Operat, Seattle, WA USA
[14] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[15] San Camillo Forlanini Hosp, Rome, Italy
[16] Clin Univ St Luc, Brussels, Belgium
[17] Royal Marsden Hosp, Sutton, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.5067
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5067
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Molina, A. M.
    Christos, P. J.
    Whang, Y.
    Nordquist, L.
    Hackett, A. L.
    Beltran, H.
    Faltas, B.
    Nanus, D.
    Giannakakou, P.
    Tagawa, S. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Results of a multicenter phase I/II trial of abiraterone acetate plus BEZ235 in metastatic, castration-resistant prostate cancer (mCRPC)
    Siegel, Adam Phillip
    Bryce, Alan Haruo
    Lin, Amy M.
    Friedlander, Terence W.
    Hsieh, Andrew Caleb
    Hang, Evelyn
    Weinberg, Vivian K.
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Results of a phase II trial of abiraterone acetate (AA) combined with dutasteride (DUT) for men with metastatic castration resistant prostate cancer (mCRPC).
    McKay, Rana R.
    Werner, Lillian
    Zukotynski, Katherine A.
    Domachevsky, Liran
    Elfiky, Aymen
    Pomerantz, Mark M.
    Bubley, Glenn J.
    Montgomery, Robert B.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [34] Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study
    Posadas, Edwin M.
    Chi, Kim N.
    de Wit, Ronald
    de Jonge, Maja J. A.
    Attard, Gerhardt
    Friedlander, Terence W.
    Yu, Margaret K.
    Hellemans, Peter
    Chien, Caly
    Abrams, Charlene
    Jiao, Juhui J.
    Saad, Fred
    CLINICAL CANCER RESEARCH, 2020, 26 (14) : 3517 - 3524
  • [35] Final Overall Survival (OS) Analysis of COU-AA-301, a Phase 3 Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pretreated With Docetaxel
    Fizazi, K.
    Scher, H. I.
    Molina, A.
    Logothetis, C. J.
    Jones, R. J.
    Staffurth, J. N.
    Li, J.
    Kheoh, T.
    Haqq, C. M.
    de Bono, J. S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S483 - S484
  • [36] KEYNOTE-365 COHORT D: PEMBROLIZUMAB PLUS ABIRATERONE ACETATE AND PREDNISONE IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Piulats, Josep
    Ferrario, Cristiano
    Linch, Mark
    Stoeckle, Michael
    Laguerre, Brigitte
    Arranz, Jose
    Todenhoefer, Tilman
    Fong, Peter
    Berry, William
    Emmenegger, Urban
    Mourey, Loic
    Mar, Nataliya
    Appleman, Leonard
    Joshua, Anthony
    Conter, Henry
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A378 - A378
  • [37] Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
    Chi, Kim N.
    Fleshner, Neil
    Chiuri, Vincenzo Emanuele
    Van Bruwaene, Siska
    Hafron, Jason
    McNeel, Douglas G.
    De Porre, Peter
    Maul, Raymond Scott
    Daksh, Mahesh
    Zhong, Xiaogang
    Mason, Gary E.
    Tutrone, Ronald F.
    ONCOLOGIST, 2023, 28 (05): : E309 - E312
  • [38] Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) - a Drug-Drug Interaction (DDI) Study With Dextromethorphan HBr and Theophylline
    Chi, K. N.
    Tolcher, A.
    Lee, P.
    Rosen, P.
    Molina, A.
    Jiao, J.
    Bernard, A.
    Tran, N.
    Acharya, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S502 - S503
  • [39] A randomized phase II cross-over study of abiraterone plus prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration resistant prostate cancer (mCRPC).
    Chi, Kim N.
    Annala, Matti
    Sunderland, Katherine
    Khalaf, Daniel
    Finch, Daygen
    Oja, Conrad D.
    Vergidis, Joanna
    Zulfiqar, Muhammad
    Beja, Kevin
    Vandekerkhove, Gillian
    Gleave, Martin
    Wyatt, Alexander William
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
    Danila, Daniel C.
    Morris, Michael J.
    de Bono, Johann S.
    Ryan, Charles J.
    Denmeade, Samuel R.
    Smith, Matthew R.
    Taplin, Mary-Ellen
    Bubley, Glenn J.
    Kheoh, Thian
    Haqq, Christopher
    Molina, Arturo
    Anand, Aseem
    Koscuiszka, Michael
    Larson, Steve M.
    Schwartz, Lawrence H.
    Fleisher, Martin
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1496 - 1501
12345